Navigation Links
ACORN CRO Continues Growth in Strong Third Quarter
Date:11/10/2008

Oncology Focused Contract Research Organization Exceeds Expectations

MEMPHIS, Tenn., Nov. 10 /PRNewswire/ -- ACORN CRO, a Contract Research Organization exclusively focused on oncology, announced today that its third quarter had once again exceeded projections as the company continues to experience banner growth. "The industry has responded favorably to ACORN's ability to consistently exceed client expectations, and we are ahead of projections in both number of projects, patients accrued, and revenue generated. Our strong, active relationship with community oncology and its physicians along with our proprietary technology provide sponsors with a combination for success," remarked Steve Coplon, ACORN CEO.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081110/CLM032LOGO )

ACORN CRO currently provides services for both specific cancer types and supportive care studies with additional projects ready to launch in the near future. Positioned for continued growth in 2009, ACORN CRO has expanded its staff and capabilities. ACORN CRO's experienced team provides sponsors with Project and Site Management; Data Management via Guardian EDC(TM); Statistics and Statistical Programming; and Medical and Scientific Writing.

Founded in community oncology and grounded with the most stringent scientific disciplines, ACORN CRO seamlessly incorporates the best of both worlds. "Though ACORN operates with a strong business model focused on operational success, scientific excellence guides our organization," according to Dr. Lee Schwartzberg, President and Chief Medical Director. Nationally recognized for his commitment to research at the community level, Dr. Schwartzberg co-founded Accelerated Community Oncology Research Network (ACORN), enabling oncologists nationwide to provide their patients the most promising research initiatives.

ACORN CRO evolved in response to sponsor requests for value-driven quality solutions and accelerated patient accruals. With a team approach, ACORN CRO lends itself to highly efficient and accurate trial operations. Close working relationships with community oncology practices enable prompt accruals.

"The trajectory of ACORN CRO for 2009 portends the most successful year for our company," stated Coplon. "We look forward to seeing sponsors at various meetings to showcase our abilities."

For additional information visit http://www.ACORNresearch.net or contact Liz Conway, Director of Marketing and Corporate Services, 901-259-0878.

ACORN CRO

ACORN CRO is a full-service, oncology-focused contract research organization, providing value-driven, quality solutions to the pharmaceutical and biotech industry and offering unparalleled customer service in monitoring; clinical data management; statistical analysis; medical writing and project management. ACORN CRO delivers insights from key oncology opinion leaders and accelerates the research process through advanced levels of efficiency.

Contact Information:

Liz Conway

(901) 435-5570

lconway@sosacorn.com

http://www.ACORNresearch.net

Deborah D. Coble

901-683-0055 x1312

dcoble@sosacorn.com


'/>"/>
SOURCE ACORN CRO
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development
2. ACORN Expands Oncology Information Portfolio With Comprehensive Data Warehouse
3. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
4. Acorn Acquisition Corp Announces Definitive Agreement to Acquire Lumen Medical Inc.
5. ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results
6. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
7. FDA Continues Review of Takedas New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
8. Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets
9. Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis?
10. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
11. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):